INDEX OF SUBJECTS FOR VOLUME 21

Aeromonas
A. hydrophila, experimental infection in mice, 311
haemagglutinin production, 319
Adhesion
B. fragilis to red cells, 105
Candida to denture acrylic, 209
E. coli to guinea pig intestine, 117
Klebsiella to CSF shunts, 225
leptospires to renal epithelial cells, 59
Alkalescens-Dispar group, 337
Alkaline phosphatase
production by *V. choierae*, 13
Anaerobiosis (see also *Bacteroides* and clostridia)
phenotypic changes in mycobacteria, 251
Antibiotics and other antibacterial substances
benzylpenicillin, hydrolysis by *Bacteroides*, 49
cefotaxime, cefoperazone and latamoxef, 203
cefoxitin, hydrolysis by *Bacteroides*, 49
cefoxitin, β-lactamase induction, 203
chlorhexidine treatment of denture acrylic, 209
clavulanic acid, effect on *Bacteroides*, 49
Cl. difficile-mediated diarrhoea, 299
imipenem, hydrolysis by *Bacteroides*, 49
latamoxef, hydrolysis by *Bacteroides*, 49
lincomycin and *V. cholerae* exoprotein production, 13
selective therapy in mixed infections, 93
sensitivity of fusobacteria, 93
Haemophilus, 219
Klebsiella, 125
Streptobacillus moniliformis, 39
tuberculosis chemotherapy and antibody response, 257
Antibiotic resistance
and adhesion of *Klebsiella* to CSF shunts, 225
β-lactamases, inducible, 203
β-lactamases of *Bacteroides*, 49
cefoxitin, cefotaxime, cefoperazone and latamoxef, 203
gentamicin, and slime glycolipoprotein in *Ps. aeruginosa*, 199
transduction of streptomycin resistance in streptococci A and G, 69
R-plasmid transfer *in vivo*, 325
Antigens
glycoproteins of *Str. faecalis*, 161
API tests
API 20 strep, 189
API 20E, comparison with quantum II BID, 145, 215
API ZYM tests for *Streptobacillus moniliformis*, 39
Appendicitis, role of *B. fragilis*, 245
Aspergillus fumigatus, C-reactive protein binding, 173
Automation
Bactec system, 215
quantum II BID identification system, 145, 215
Septi-check system, 215

Bacteraemia
campylobacters in children, 1
Bacteroides
B. fragilis antibodies, 343
B. fragilis, *B. vulgatus*, synergy with *E. coli*, 43
B. fragilis group haemagglutination, 105
B. fragilis in appendicitis, 245
β-lactamases of *B. fragilis* group, 49
B. melaninogenicus/oralis in dental abscesses, 101
B. ureolyticus identification, 109
synergy with fusobacteria, 93
Biotyping
campylobacters, 1
E. coli, Alkalescens-Dispar, 337
G. vaginalis, 357
Haemophilus from conjunctivitis, 219
H. influenzae, *parainfluenzae*, 349
Blastomyces dermatitidis, 7
BOOKS RECEIVED
A dictionary of genetics (R C King and W D Stansfield), 361
Advances in biotechnological processes, vol. 3 (edited by A Mizrahi and A L van Wezel), 187
Bacterial meningitis (edited by M A Sande *et al.*), 361
Chemical methods in bacterial systematics (edited by M Goodfellow and D E Minnikin), 361
Cystic fibrosis: horizons (edited by D Lawson), 92
Environmental regulation of microbial metabolism (edited by I S Kulaeu *et al.*), 279
Genetics of bacteria (edited by J Scaife *et al.*), 279
Genome rearrangement (edited by M Simon and I Herkskowitz), 280
Germ free research. Microflora control and its applications to the biomedical sciences (edited by B S Worstman), 280
Herpetic eye diseases (edited by P C Mandgal and L Missotten), 361
Interferon 6 (edited by I Gresser), 361
Laboratory animal medicine (edited by J G Fox *et al.*), 92
Methods in microbiology, vol 15 (edited by T Bergan), 91
Molecular components of hepatitis B virus (M Feitelson), 282
Repairable lesions in microorganisms (edited by A Hurst and A Nasim), 281
The biology of the actinomyces (edited by M Goodfellow *et al.*), 91
The virulence of *Escherichia coli*. Review and methods (edited by M Sussman), 279
Viral messenger RNA. Transcription, processing, splicing and molecular structure (edited by U Becker), 280
Bordetella pertussis, heat-labile toxin, 265

Campylobacter
biotyping and serotyping, 1
C. jejuni and *C. coli* in children, 1
serotyping by co-agglutination, 83

Candida
adhesion to denture acrylic, 209
effect of saliva and serum on adhesion, 209
Capsules
and virulence in fusobacteria, 93
of *Klebsiella*, phagocytosis, 125
Cell mediated immunity
enteric fever salmonellae, cross reactivity, 233
in tuberculosis, 257
to atypical mycobacteria, 35
Chemiluminescence
immunoassay for leptospires, 353
polymorphs and *Klebsiella*, 133
Cholera toxin, 13
Clostridia
C. difficile, colonisation resistance, 299
C. difficile toxin production, 293, 299
Colonisation resistance to *Cl. difficile*, 299
Complement
opsonisation of *Klebsiella*, 125
Conjugation
R-plasmid transfer *in vivo*, 325
transfer of *Ps. aeruginosa* mucoid character, 331
Conjunctivitis, *Haemophilus* spp. from infants, 219
Coxsackie B virus and myocardial infarction, 287
CSF shunts
adhesion of *Klebsiella*, 225
C-reactive protein
binding to *Aspergillus*, 173
Cystic fibrosis
Ps. aeruginosa LPS, 179
Ps. aeruginosa, transfer of mucoid character, 331
types of *Ps. aeruginosa*, 179

Dento-alveolar abscesses, quantitative bacteriology, 101
DNAase
production by *V. cholerae*, 13
DNA analysis
of *B. ureolyticus*, 109

Electronmicroscopy
Polymorphs, macrophages and salmonellae, 151
ELFA (enzyme-linked fluorescence assay)
IgM to HBcAg, 271
ELISA
Coxsackie B virus IgM antibodies, 287
CRP binding to *Aspergillus*, 173
IgM to HBcAg, comparison with ELFA, 271
M. tuberculosis antibodies, 257
rubella IgA and IgG, 283
with *Ps. aeruginosa* monoclonal antibodies, 87
Endocarditis
antigens of *Str. faecalis*, 161
Endotoxins (see also Lipopolysaccharide (LPS))
A. hydrophila in mice, 311
Enteric fever
cell mediated immunity, 233
Enterobacteria
cefoxitin sensitivity, 203
identification by quantum II BID, 145, 215
inducible β-lactamases, 203
Entero-invasive *E. coli*, adhesion, 117
Enterotoxins
of *S. tymphimurium*, 19
rabbit ileal loop test, 19
tissue culture test, 19
Escherichia coli
adhesion to guinea pig intestine, 117
Alkalescens-Dispar group, 337
entero-invasive strains, adhesion, 117
LPS of strain J5, 25
R-plasmid transfer *in vivo*, 325
synergy with *Bacteroides*, 43
synergy with fusobacteria, 93
Exotoxins
Bord. pertussis, heat labile, 265
Cl. difficile A and B, 293

Faecal bacteria
colonisation resistance to *Cl. difficile*, 299
occurrence of *Pr. vulgaris*, *Pr. mirabilis* and *M. morgani*, 139
Fimbriae
Alkalescens-Dispar group, 337
Fusobacteria
in mixed infections, pathogenicity, 93

Gardnerella vaginalis, biotyping, 357
Gastroenteritis
campylobacters in children, 1
haemagglutinin-producing *Aeromonas*, 319
incidence of *Pr. vulgaris*, *Pr. mirabilis* and *M. morgani*, 139
Genetic mapping
Ps. aeruginosa mucoid locus, 331
Genital-tract infection
G. vaginalis, 357
Haemophilus spp., 349

Haemagglutination
by *B. fragilis* group, 105
haemagglutinin of *Aeromonas*, 319
passive, 343
S. aureus protein A-antibody-mediated detection of *B. fragilis* antibodies, 343
Haemophilus
biotyping, 219
characterisation, 219
conjunctivitis in infants, 219
H. influenzae, type b LPS, 25
H. influenzae, *parainfluenzae* from genital tract, 349
outer-membrane proteins, 219
plasmids, 219
selective culture medium, 349
Haverhill fever, 39
Hepatitis B
ELFA and ELISA for IgM to HBcAg, 271
Hydrophobicity
Aspergillus fumigatus, 173
Klebsiella surface, 125

Immunisation
H. influenzae type b and *E. coli* J5 LPS, 25
of mice against *Blastomyces*, 7
of mice with enteric fever salmonellae, 233
rubella, antibody responses, 283

Klebsiella
adhesion to CSF shunts, 225
antimicrobial susceptibility, 125
K. aerogenes surface hydrophobicity, 125
K antigens as virulence factors, 133
O and K antigens, 125
phagocytosis, 125
synergy with fusobacteria, 93

Lectins
and glycoprotein antigens of *Str. faecalis*, 161
Leptospires
adhesion to renal epithelial cells, 59
detection by chemiluminescent immunoassay, 353
Leukocytes (see polymorphonuclear leukocytes), 125
Lipopolysaccharide (LPS)
chick embryo test, 25
H. influenzae type b and *E. coli* J5, 25
of *Ps. aeruginosa* in cystic fibrosis, 179
serology, 25

Macrophages
activation by enteric fever salmonellae, 233
fungicidal activity, 7
phagocytosis of salmonellae, electronmicroscopy, 151
Monoclonal antibodies
against *Ps. aeruginosa*, 87
anti-phosphorylcholine, 173
anti-subclass, IgG and IgA, in rubella serology, 283
Morganella morgani
in faeces, 139
Mycobacteria
atypical mycobacteria, 35
cell mediated immunity in mice, 35
identification, 251
M. tuberculosis, 35
M. tuberculosis antibodies, detection, 257
phenotypic changes in anaerobic conditions, 251
Myocardial infarction, coxsackie B virus infection, 287

Non-gonococcal urethritis
role of *B. ureolyticus*, 109

Opsonisation
Klebsiella by serum, 133
of *Klebsiella*, 125

PAGE
Haemophilus, outer-membrane proteins, 219
LPS of *Ps. aeruginosa*, 179
membrane proteins of *Klebsiella*, 225
of *B. ureolyticus*, 109
of *Str. faecalis* proteins, 161
S. aureus supernates, 169
PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND
Proceedings of the 152nd meeting, (after i)
Pathophysiology, *A. hydrophila* in mice, 311
Peptococci in dental abscesses, 101
Phagocytosis
Blastomyces by macrophages, 7
Klebsiella by polymorphs, 125, 133
salmonellae by polymorphs and macrophages, electronmicroscopy, 151
Pigment production
by group-B streptococci, 75
Plasmids
analysis in *E. coli*, 325
and adhesion in multiresistant *Klebsiella*, 225
and virulence in *S. dublin*, 239
Haemophilus spp., 219
pM060-mediated conjugation in *Ps. aeruginosa*, 331
R-plasmid transfer *in vivo*, 325
transfer of *Ps. aeruginosa* mucoid character, 331
Polymorphonuclear leukocytes
electronmicroscopy, 151
phagocytosis of *Klebsiella*, 125, 133
Prednisolone and meclofenamate, effect on *Bord. pertussis* toxin, 265
Protease
production by *V. cholerae*, 13
Protein synthesis
Cl. difficile cytotoxin, 299
Cl. difficile toxins A and B, 293
effect of lincomycin on *V. cholerae*, 13
haemagglutinin of *Aeromonas*, 319
slime glycolipoprotein of *Ps. aeruginosa*, 199
S. aureus extracellular proteins, 169
Proteus
Pr. mirabilis and *M. morgani* in faeces, 139
Pr. vulgaris in faeces and UTI, 139
Pseudomonas
identification by quantum II BID, 215
inducible β-lactamases, 203
LPS of *Ps. aeruginosa*, 179
Ps. aeruginosa monoclonal antibodies, 87
Ps. aeruginosa, slime glycolipoprotein and gentamicin resistance, 199
Ps. aeruginosa, transfer of mucoid character, 331
Ps. aeruginosa types in cystic fibrosis, 179

Quantum II BID identification system, 145, 215
Quantitative bacteriology
of dento-alveolar abscesses, 101

Renal epithelial cells
adhesion of leptospires, 59
Rubella, IgA and IgG responses in man, 283

Saliva, effects on *Candida* adhesion, 209
Salmonellae
S. dublin, TnA and virulence, 239
S. typhi and cell mediated immunity, 35
S. typhi, paratyphi, cell mediated immunity, 233

Salmonellae (*cont.*)
S. typhi, paratyphi, macrophage activation, 233
S. typhimurium enterotoxin, 19
Serology
B. fragilis antibodies, 343
B. fragilis antibodies in appendicitis, 245
Coxsackie B virus IgM in myocardial infarction, 287
ELFA and ELISA for IgM to HBcAg, 271
M. tuberculosis antibodies, 257
S. aureus protein A-antibody-mediated haemagglutination, 343
chemiluminescent immunoassay for leptospires, 353
IgA, IgG responses to rubella virus, 283
Serotyping
campylobacters, 1, 83
group-G streptococci, 275
S. aureus by Western Blot, 169
Serum
bactericidal action on *Ps. aeruginosa*, 179
effect on *Candida* adhesion, 209
effect on macrophage fungicidal activity, 7
opsonisation of *Klebsiella*, 125, 133
Slime glycolipoprotein of *Ps. aeruginosa*, 199
Staphylococci
S. aureus for co-agglutination, 83
S. aureus protein A-antibody-mediated haemagglutination, 343
S. aureus typing by Western Blot, 169
synergy with fusobacteria, 93
Streptobacillus moniliformis
characterisation and antibiotic susceptibility, 39
Streptococci
glycoprotein antigens of *Str. faecalis*, 161
groups A and G, transduction, 69
group B, pigment production, 75
group-G, serotyping, 275
M± SOR± variants of groups A and G, 69
Str. milleri in dental abscesses, 101
Str. sanguis and *Str. mitior*, differentiation, 189
synergy with fusobacteria, 93
Surface antigens
K of *Klebsiella*, 133
O, I of *Klebsiella*, 125
Synergy
E. coli and *Bacteroides*, 43
fusobacteria and other bacteria, 93

Transduction
in groups A and G streptococci, 69
Transposons
Tn*A* in *S. dublin*, virulence, 239
Toxins (see also Enterotoxins)
Cl. difficile cytotoxin, 299
V. cholerae, effect of lincomycin, 13

Urinary tract infection
Pr. vulgaris in UTI, 139

Virulence factors
haemagglutinin of *Aeromonas*, 319
of *Klebsiella*, 133
of salmonellae, 151
plasmids in *S. dublin*, 239

Western Blotting
of *S. aureus* supernates, 169
of *Str. faecalis* antigens, 161
Whooping cough
anti-inflammatory agents, 265
Bord. pertussis heat-labile toxin, 265

INDEX OF AUTHORS FOR VOLUME 21

ADLER B, *see* BALLARD *et al.*, 59

AITCHISON EILEEN J, LAMBERT P A, FARRELL I D. Antigenic composition of an endocarditis-associated isolate of *Streptococcus faecalis* and identification of its glycoprotein antigens by ligand blotting with lectins, 161

AL-ADNANI M S, *see* ELHAG *et al.*, 245

ALEMOHAMMAD M M, *see* FRICKER *et al.*, 83

ALWAN M H, *see* ELHAG *et al.*, 245

ANDERSEN P, *see* JENSEN *et al.*, 173

ARSENIS G, DIMITRACOPOULOS G. Chemical composition of the extracellular slime glycolipoprotein of *Pseudomonas aeruginosa* and its relation to gentamicin resistance, 199

ASCHE V, *see* MACGEORGE *et al.*, 331

ASHKENAZI S. Adherence of non-fimbriate entero-invasive *Escherichia coli* O124 to guinea pig intestinal tract *in vitro* and *in vivo*, 117

BAIRD G D, *see* MANNING *et al.*, 239

BALLARD S A, WILLIAMSON M, ADLER B, VINH T, FAINE S. Interactions of virulent and avirulent leptospires with primary cultures of renal epithelial cells, 59

BARCLAY FIONA E, *see* BORRIELLO AND BARCLAY, 299

BARCLAY G R, YAP P L, MCCELLAND D B L, JONES R J, ROE ELIZABETH A, MCCANN MOIRA C, MICKLEM LISEL R, JAMES K. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent *Pseudomonas aeruginosa* vaccine, 87

BARTON L L, *see* GILLESPIE *et al.*, 251

BELL T A, *see* ROBERTS *et al.*, 219

BENITO R, VAZQUEZ J A, BERRON S, FENOLL A, SAEZ-NIETO J A. A modified scheme for biotyping *Gardnerella vaginalis*, 357

BERRON S, *see* BENITO *et al.*, 357

BOOTH J C, *see* HANNINGTON *et al.*, 287

BORRIELLO S P, BARCLAY FIONA E. An *in vitro* model of colonisation resistance to *Clostridium difficile* infection, 299

BOWES R JANE, *see* HANNINGTON *et al.*, 287

BRENDEN RITA A, HUIZINGA H W. Pathophysiology of experimental *Aeromonas hydrophila* infection in mice, 311

BROADBENT D A, *see* YOUNG AND BROADBENT, 13

BROOK I, WALKER R I. The relationship between *Fusobacterium* species and other flora in mixed infection, 93

BROWN M R W, *see* WILLIAMS *et al.*, 125

BRUMMER E, *see* SUGAR *et al.*, 7

BUNDELL CHRISTINE S, *see* STEWART *et al.*, 319

BURDON D W, *see* HASLAM *et al.*, 293

BURKE VALERIE *see* STEWART *et al.*, 319

CANDY D C A, *see* WALLIS *et al.*, 19

CANDY D C A, *see* HASLAM *et al.*, 293

CARSON P B D, *see* MORITZ AND CARSON, 203

CHESHAM J S, *see* PLATT *et al.*, 325

CHRICHTON PAMELA B, *see* OLD AND CHRICHTON, 337

CONGI ROSA V, *see* LASTOVICA *et al.*, 1

COOKE E MARY, *see* PITT *et al.*, 179

DAVE J R, TAYLOR P, GRANGE J M, GAYA H. A new enzyme-linked fluorescence assay (ELFA) for use with peroxidase-antibody conjugates: a comparison with ELISA for the quantitation of IgM antibodies to hepatitis B core antigen, 271

DAWSON CHRISTINE A, *see* TAYLOR *et al.*, 109

DENOYA C D, TREVISAN A R, ZORZOPULOS J. Adherence of multiresistant strains of *Klebsiella pneumoniae* to cerebrospinal fluid shunts: correlation with plasmid content, 225

DIMITRACOPOULOS G, *see* ARSENIS AND DIMITRACOPOULOS, 199

DOSUNMU-OGUNBI O, *see* LAWAL AND DOSUNMU-OGUNBI, 275

EDWARDS R, FINCH R G. Characterisation and antibiotic susceptibilities of *Streptobacillus moniliformis*, 39

ELEY A, GREENWOOD D. Beta-lactamases of type culture strains of the *Bacteroides fragilis* group and of strains that hydrolyse cefoxitin, latamoxef and imipenem, 49

ELHAG K M, ALWAN M H, AL-ADNANI M S, SHERIF R A. *Bacteroides fragilis* is a silent pathogen in acute appendicitis, 245

FAINE S, *see* BALLARD *et al.*, 59

FARRELL I D, *see* AITCHISON *et al.*, 161

FENOLL A, *see* BENITO *et al.*, 357

FINCH R G, *see* EDWARDS AND FINCH, 39

FRENCH G L, *see* PRICE *et al.*, 189

FRICKER C R, URADZINSKI J, ALEMOHAMMAD M M, PARK R W A, WHELAN C, GIRDWOOD R W A. Sterotyping of campylobacters by co-agglutination on the basis of heat-stable antigens, 83

GAYA H, *see* DAVE *et al.*, 271

GILLESPIE J, BARTON L L, RYPKA E W. Phenotypic changes in mycobacteria grown in oxygen-limited conditions, 251

GIRDWOOD R W A, *see* FRICKER *et al.*, 83

GRAHAME R, *see* STOKES *et al.*, 283

GRANGE J M, *see* DAVE *et al.*, 271

GREENWOOD D, *see* ELEY AND GREENWOOD, 49

GUO YAN-NIE HSU H S, MUMAW V R, NAKONECZNA IRENE. Electronmicroscopy studies on the bactericidal action of inflammatory leukocytes in murine salmonellosis, 151

HADDON S J, *see* WALLIS *et al.*, 19

HAIGH C G, *see* WILLIAMS *et al.*, 125

HANNINGTON GILLIAN, BOOTH J C, BOWES R JANE, STERN H. Coxsackie B virus-specific IgM antibody and myocardial infarction, 287

HASLAM S C, KETLEY J M, MITCHELL T J, STEPHEN J, BURDON D W, CANDY D C A. Growth of *Clostridium difficile* and production of toxins A and B in complex and defined media, 293
HENRICHSEN C, *see* STEVENS *et al.*, 145
HILL MOLLY R, MCKINNEY K L, MARKS M I, HYDE R M. Comparative analysis of *Haemophilus influenzae* type b and *Escherichia coli* J S lipopolysaccharides, 25
HOLLOWAY B W, *see* MACGEORGE, 331
HOLMES K K, *see* ROBERTS *et al.*, 219
HOOKEY J V, *see* WAITKINS AND HOOKEY, 353
HUIZINGA H W, *see* BRENDEN AND HUIZINGA, 311
HYDE R M, *see* HILL *et al.*, 25

JAMES K, *see* BARCLAY *et al.*, 87
JENSEN TINE D BØRGLUM, SCHØNHEYDER H, ANDERSEN P, STENDERUP A. Binding of C-reactive protein to *Aspergillus fumigatus* fractions, 173
JONES P W, *see* MANNING *et al.*, 239
JONES R J, *see* BARCLAY *et al.*, 87

KAMAT R S, *see* KULKARNI AND KAMAT, 35
KAMAT R S, *see* TIWARI AND KAMAT, 233
KETLEY J M, *see* HASLAM *et al.*, 293
KOROLIK V, *see* MACGEORGE *et al.*, 331
KRAMBOVITIS E. Detection of antibodies to *Mycobacterium tuberculosis* plasma membrane antigen by enzyme-linked immunosorbent assay, 257
KRIKLER S J, PENNINGTON T H, PETRIE DIANE. Typing of strains of *Staphylococcus aureus* by Western Blot analysis of culture supernates, 169
KRISTINSSON K G, *see* PLATT *et al.*, 325
KULKARNI SWATI, KAMAT R S. Cross-reactions in cell mediated immunity induced by atypical mycobacteria, 35

LAMBERT P A, *see* WILLIAMS *et al.*, 125
LAMBERT P A, *see* AITCHISON *et al.*, 161
LASTOVICA A J, LE ROUX ELZA, CONGI ROSA V, PENNER J L. Distribution of sero-biotypes of *Campylobacter jejuni* and *C. coli* isolated from paediatric patients, 1
LAWAL S F, DOSUNMU-OGUNBI O. A new scheme for serotyping group-G streptococci, 275
LE ROUX ELZA, *see* LASTOVICA *et al.*, 1
LESLIE D L, *see* SENIOR AND LESLIE, 139
LEWIS M A O, MACFARLANE T W, MCGOWAN D A. Quantitative bacteriology of acute dento-alveolar abscesses, 101

MCCANN MOIRA C, *see* BARCLAY *et al.*, 87
MCCELLAND D B L, *see* BARCLAY *et al.*, 87
MCCOURTIE J, MACFARLANE T W, SAMARANAYAKE L P. Effect of saliva and serum on the adherence of *Candida* species to chlorhexidine-treated denture acrylic, 209
MACDOUGALL JANE, *see* PITT *et al.*, 179
MACFARLANE T W, *see* LEWIS *et al.*, 101
MACFARLANE T W, *see* MCCOURTIE *et al.*, 209
MACGEORGE J, KOROLIK V, MORGAN A F, ASCHE V, HOLLOWAY B W. Transfer of a chromosomal locus responsible for mucoid colony morphology in *Pseudomonas aeruginosa* isolated from cystic fibrosis patients to *P. aeruginosa* PAO, 331
MCGOWAN D A, *see* LEWIS *et al.*, 101
MCKINNEY K L, *see* HILL *et al.*, 25
MACLAREN D M, *see* VERWEIJ-VAN VUGHT *et al.*, 43
MACLAREN D M, *see* VEL *et al.*, 105
MACLAREN D M, *see* SIMOONS-SMIT *et al.*, 133
MANNING E J, BAIRD G D, JONES P W. The role of plasmid genes in the pathogenicity of *Salmonella dublin*, 239
MARIAN A, *see* VEL *et al.*, 105
MARKS M I, *see* HILL *et al.*, 25
MICKLEM LISEL R, *see* BARCLAY *et al.*, 87
MIMS C A, *see* STOKES *et al.*, 283
MITCHELL T J, *see* HASLAM *et al.*, 293
MORGAN A F, *see* MACGEORGE *et al.*, 331
MORITZ V A, CARSON P B D. Cefoxitin sensitivity as a marker for inducible beta-lactamases, 203
MUMAW V R, *see* GUO *et al.*, 151

NAKONECZNA IRENE, *see* GUO *et al.*, 151
NAMAVAR F, *see* VERWEIJ-VAN VUGHT *et al.*, 43
NAMAVAR F, *see* VEL *et al.*, 105
OLD D C, CHRICHTON PAMELA B. P fimbriation among biochemically inactive strains of *Escherichia coli* of the group formerly called Alkalescens-Dispar, 337
OSBORNE M P, *see* WALLIS *et al.*, 19
OWEN R J, *see* TAYLOR *et al.*, 109

PARISH G T, *see* STEVENS AND PARISH, 215
PARK R W A, *see* FRICKER *et al.*, 83
PARTON R. Effect of anti-inflammatory agents on the haemorrhagic response of mouse skin to *Bordetella pertussis* heat-labile toxin, 265
PENKETH ANDREA R L, *see* PITT *et al.*, 179
PENNER J L, *see* LASTOVICA *et al.*, 1
PENNINGTON T H, *see* KRIKLER *et al.*, 169
PETRIE DIANE, *see* KRIKLER *et al.*, 169
PHILLIPS I, *see* PRICE *et al.*, 189
PITT T L, MACDOUGALL JANE, PENKETH ANDREA R L, COOKE E MARY. Polyagglutinating and non-typable strains of *Pseudomonas aeruginosa* in cystic fibrosis, 179
PLATT D J, CHESHAM J S, KRISTINSSON K G. R-Plasmid transfer *in vivo*: a prospective study, 325
PRICE T, FRENCH G L, TALSANIA H, PHILLIPS I. Differentiation of *Streptococcus sanguis* and *S. mitior* by whole-cell rhamnose content and possession of arginine dihydrolase, 189
PUBBEN ANJA N B, *see* VEL *et al.*, 105
RAO R S, *see* SRINIVASAKUMAR AND RAO, 343

ROBERTS M C, BELL T A, SANDSTROM K I, SMITH A L, HOLMES K K. Characterisation of *Haemophilus* spp. isolated from infant conjunctivitis, 219
ROE ELIZABETH A, *see* BARCLAY *et al.*, 187
RYPKA E W, *see* GILLESPIE *et al.*, 251

SAEZ-NIETO J A, *see* BENITO *et al.*, 357

SAMARANAYAKE L P, *see* MCCOURTIE *et al.*, 209
SANDSTROM K I, *see* ROBERTS *et al.*, 219
SCHØNHEYDER H, *see* JENSEN *et al.*, 173
SENIOR B W, LESLIE D L. Rare occurrence of *Proteus vulgaris* in faeces: a reason for its rare association with urinary tract infections, 139
SHERIF R A, *see* ELHAG *et al.*, 245
SIMOONS-SMIT A M, VERWEIJ-VAN VUGHT A M J J, MACLAREN D M. The role of K antigens as virulence factors in *Klebsiella*, 133
SKJOLD S A, WANNAMAKER L W. Surfaces proteins in the transduction of groups A and G streptococci, 69
SMITH A L, *see* ROBERTS *et al.*, 219
SMITH M, *see* STEVENS *et al.*, 145
SPARRIUS M, *see* VERWEIJ-VAN VUGHT *et al.*, 43
SRINIVASAKUMAR N, RAO R S. *Staphylococcus aureus* protein A-antibody-mediated haemagglutination for the analysis of cross-reactivity between phenol-water extracts of *Bacteroides fragilis*, 343
STARKEY W G, *see* WALLIS *et al.*, 19
STENDERUP A, *see* JENSEN *et al.*, 173
STEPHEN J, *see* WALLIS *et al.*, 19
STEPHEN J, *see* HASLAM *et al.*, 293
STERN H, *see* HANNINGTON *et al.*, 287
STEVENS D A, *see* SUGAR *et al.*, 7
STEVENS M, HENRICHSEN C, SMITH M. A collaborative evaluation of a rapid, semi-automated identification system for gram-negative bacilli: the Quantum II BID, 145
STEVENS M, PARISH G T. Rapid identification of gram-negative bacilli from blood cultures, 215
STEWART G A, BUNDELL CHRISTINE S, BURKE VALERIE. Partial characterisation of a soluble haemagglutinin from human diarrhoeal isolates of *Aeromonas*, 319
STOKES ANN, MIMS C A, GRAHAME R. Subclass distribution of IgG and IgA responses to rubella virus in man, 283
STURM A W. Isolation of *Haemophilus influenzae* and *Haemophilus parainfluenzae* from genital-tract specimens with a selective culture medium, 349
SUGAR A M, BRUMMER E, STEVENS D A. Fungicidal activity of murine broncho-alveolar macrophages against *Blastomyces dermatitidis*, 7

TALSANIA H, *see* PRICE *et al.*, 189
TAPSALL J W. Pigment production by Lancefield-group-B streptococci (*Streptococcus agalactiae*) 75
TAYLOR A J, DAWSON CHRISTINE A, OWEN R J. The identification of *Bacteroides ureolyticus* from patients with non-gonococcal urethritis by conventional biochemical tests and by DNA and protein analyses, 109
TAYLOR P, *see* DAVE *et al.*, 271
TIWARI HEMLATTA, KAMAT R S. Cross-reactions in cell-mediated immunity to *Salmonella* causing enteric fever, 233
TREVISAN A R, *see* DENOYA *et al.*, 225

URADZINSKI J, *see* FRICKER *et al.*, 83

VAZQUEZ J A, *see* BENITO *et al.*, 357
VEL W A C, *see* VERWEIJ-VAN VUGHT *et al.*, 43
VEL W A C, NAMAVAR F, MARIAN A, VERWEIJ-VAN VUGHT A M J J, PUBBEN ANJA NB, MACLAREN D M. Haemagglutination by the *Bacteroides fragilis* group, 105
VERWEIJ-VAN VUGHT A M J J, NAMAVAR F, VEL W A C, SPARRIUS M, MACLAREN D M. Pathogenic synergy between *Escherichia coli* and *Bacteroides fragilis* or *B. vulgatus* in experimental infections: a non-specific phenomenon, 43
VERWEIJ-VAN VUGHT A M J J, *see* SIMOONS-SMIT *et al.*, 133
VERWEIJ-VAN VUGHT A M J J, *see* VEL *et al.*, 105
VINH T, *see* BALLARD *et al.*, 59

WAITKINS SHEENA A, HOOKEY J V. The detection of leptospires by a chemiluminescent immunoassay, 353
WALKER R I, *see* BROOK AND WALKER, 93
WALLIS T S, STARKEY W G, STEPHEN J, HADDON S J, OSBORNE M P, CANDY D C A. Enterotoxin production by *Salmonella typhimurium* strains of different virulence, 19
WANNAMAKER L W, *see* SKJOLD AND WANNAMAKER, 69
WHELAN C, *see* FRICKER *et al.*, 83
WILLIAMS P, LAMBERT P A, HAIGH C G, BROWN M R W. The influence of the O and K antigens of *Klebsiella aerogenes* on surface hydrophobicity and susceptibility to phagocytosis and antimicrobial agents, 125
WILLIAMSON M, *see* BALLARD *et al.*, 59

YAP P L, *see* BARCLAY *et al.*, 87
YOUNG D B, BROADBENT D A. The effect of lincomycin on exoprotein production by *Vibrio cholerae*, 13

ZORZOPULOS J, *see* DENOYA *et al.*, 225